Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Teaching | 1 | 2018 | 55 | 0.740 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 201 | 0.680 |
Why?
|
| Neoplasms | 2 | 2018 | 676 | 0.660 |
Why?
|
| Internship and Residency | 1 | 2018 | 271 | 0.580 |
Why?
|
| Breast Neoplasms | 5 | 2017 | 730 | 0.440 |
Why?
|
| Anthracyclines | 4 | 2017 | 54 | 0.390 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 600 | 0.340 |
Why?
|
| Thalidomide | 1 | 2007 | 35 | 0.340 |
Why?
|
| Scalp | 2 | 2017 | 34 | 0.330 |
Why?
|
| Alopecia | 2 | 2017 | 26 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2017 | 443 | 0.290 |
Why?
|
| Esophageal Neoplasms | 3 | 2006 | 34 | 0.230 |
Why?
|
| Taxoids | 3 | 2017 | 48 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 4 | 2017 | 59 | 0.190 |
Why?
|
| Interprofessional Relations | 1 | 2018 | 54 | 0.190 |
Why?
|
| Hypothermia, Induced | 1 | 2017 | 17 | 0.170 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 165 | 0.170 |
Why?
|
| Clinical Competence | 1 | 2018 | 302 | 0.150 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2006 | 53 | 0.150 |
Why?
|
| Radiopharmaceuticals | 2 | 2006 | 84 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 115 | 0.150 |
Why?
|
| Adult | 12 | 2017 | 8719 | 0.140 |
Why?
|
| Adenocarcinoma | 4 | 2006 | 303 | 0.140 |
Why?
|
| Humans | 16 | 2018 | 29286 | 0.140 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 230 | 0.140 |
Why?
|
| Aged, 80 and over | 8 | 2013 | 3924 | 0.140 |
Why?
|
| Aged | 12 | 2017 | 10068 | 0.140 |
Why?
|
| Middle Aged | 12 | 2017 | 11572 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2013 | 674 | 0.130 |
Why?
|
| Quality of Life | 2 | 2017 | 869 | 0.130 |
Why?
|
| Leukemia | 1 | 2013 | 44 | 0.130 |
Why?
|
| Lymphoma | 1 | 2013 | 43 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 70 | 0.130 |
Why?
|
| Female | 14 | 2017 | 18970 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 2 | 2005 | 130 | 0.120 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 232 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2017 | 184 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 343 | 0.100 |
Why?
|
| Aorta | 1 | 2009 | 116 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2013 | 3173 | 0.090 |
Why?
|
| European Continental Ancestry Group | 1 | 2013 | 1359 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 44 | 0.080 |
Why?
|
| Paclitaxel | 1 | 2007 | 82 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2007 | 180 | 0.080 |
Why?
|
| Lymphatic Metastasis | 3 | 2014 | 160 | 0.080 |
Why?
|
| Camptothecin | 2 | 2005 | 50 | 0.080 |
Why?
|
| Deoxycytidine | 2 | 2005 | 69 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 1102 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2017 | 2036 | 0.070 |
Why?
|
| Male | 9 | 2013 | 18658 | 0.070 |
Why?
|
| Survival Rate | 4 | 2013 | 857 | 0.070 |
Why?
|
| African Americans | 1 | 2013 | 1647 | 0.070 |
Why?
|
| Combined Modality Therapy | 4 | 2006 | 565 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2002 | 84 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 309 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 818 | 0.040 |
Why?
|
| Medical Illustration | 1 | 2017 | 7 | 0.040 |
Why?
|
| Cryotherapy | 1 | 2017 | 15 | 0.040 |
Why?
|
| Photography | 1 | 2017 | 38 | 0.040 |
Why?
|
| Headache | 1 | 2017 | 82 | 0.040 |
Why?
|
| Risk | 1 | 2017 | 312 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 2006 | 107 | 0.040 |
Why?
|
| Young Adult | 2 | 2013 | 2427 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2014 | 2980 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2006 | 152 | 0.040 |
Why?
|
| Receptor, erbB-2 | 1 | 2014 | 57 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 108 | 0.030 |
Why?
|
| Ergocalciferols | 1 | 2013 | 3 | 0.030 |
Why?
|
| Troponin I | 1 | 2013 | 17 | 0.030 |
Why?
|
| Hypercalcemia | 1 | 2013 | 8 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 63 | 0.030 |
Why?
|
| Mastectomy | 1 | 2013 | 64 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2013 | 261 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 211 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 259 | 0.030 |
Why?
|
| Age Factors | 1 | 2014 | 1185 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2013 | 325 | 0.030 |
Why?
|
| Half-Life | 1 | 2007 | 24 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2007 | 26 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 94 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 2105 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 2198 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 165 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2009 | 938 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 1240 | 0.020 |
Why?
|
| Esophagectomy | 1 | 2006 | 16 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 13 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2005 | 26 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 34 | 0.020 |
Why?
|
| Vomiting | 1 | 2005 | 35 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 72 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 42 | 0.020 |
Why?
|
| Diarrhea | 1 | 2005 | 58 | 0.020 |
Why?
|
| Fatigue | 1 | 2005 | 76 | 0.020 |
Why?
|
| Nausea | 1 | 2005 | 68 | 0.020 |
Why?
|
| Adolescent | 1 | 2013 | 3191 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 171 | 0.020 |
Why?
|
| Risk Factors | 1 | 2013 | 3731 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 275 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 469 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 703 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 724 | 0.020 |
Why?
|
| Disease Progression | 1 | 2005 | 603 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2002 | 12 | 0.020 |
Why?
|
| Leucovorin | 1 | 2002 | 24 | 0.020 |
Why?
|
| Ethnic Groups | 1 | 2006 | 545 | 0.020 |
Why?
|
| Neutropenia | 1 | 2002 | 30 | 0.020 |
Why?
|
| Abdominal Neoplasms | 1 | 2002 | 15 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2002 | 68 | 0.020 |
Why?
|
| Methotrexate | 1 | 2002 | 65 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2002 | 92 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2005 | 1764 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2002 | 174 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 388 | 0.010 |
Why?
|